Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT03926754

Beta 3 Agonist Treatment in Heart Failure-2 (BEAT-HF II)

Sponsor: Bornholm Hospital, Denmark

Conditions Heart Failure With Reduced Ejection Fraction NYHA Class III-IV

Interventions Mirabegron

Updated 7 times since 2019 Last updated: Apr 28, 2022 Started: Jan 23, 2017 Primary completion: Jan 21, 2021 Completion: Jan 21, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Heart Failure With Reduced Ejection Fraction NYHA Class III-IV and is currently completed. Bornholm Hospital, Denmark leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Feb 2026 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jun 2022 — Jul 2024 [monthly]

Completed PHASE2_PHASE3

Status: Enrolling By Invitation → Completed
Jan 2021 — Jun 2022 [monthly]

Enrolling By Invitation PHASE2_PHASE3

▶ Show 2 earlier versions

Nov 2020 — Jan 2021 [monthly]

Enrolling By Invitation PHASE2_PHASE3
May 2019 — Nov 2020 [monthly]

Enrolling By Invitation PHASE2_PHASE3

First recorded

Jan 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bornholm Hospital, Denmark
Henning Bundgaard
Herlev Hospital
Hillerød hospital, Denmark
Hvidovre University Hospital
Royal North Shore Hospital
University Hospital Bispebjerg and Frederiksberg

Data source: Rigshospitalet, Denmark

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark